Principal Investigator

Principal Investigator

NASH/CIRRHOSIS

Sponsor: Akero, Inc

Protocol Title: “SYMMETRY”- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)”

Protocol # AK-US-001-0103 (Radiology involvement Dexa, USs, Liver Biopsy, possible MRIs)

2020-Current (Recruiting)

 

 

Principal Investigator

NASH

Sponsor: Akero, Inc

Protocol Title: “HARMONY- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects with Nonalcoholic Steatohepatitis (NASH)”

Protocol # AK-US-001-0102 (Radiology involvement Dexa, Liver Biopsy, MRIs)

 

Principal Investigator

NASH

Sponsor: Viking Therapeutics, Inc

Protocol Title: “VOAGE- A Phase 2b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of VK2809 Administered for 52 Weeks Followed by 4 Weeks Off-Drug Phase in Subjects with Biopsy Proven Nonalcoholic Steatohepatitis with Fibrosis”

Protocol # VK2809-202 (Radiology involvement Liver Biopsy, MRIs)

 

Principal Investigator

NASH

Sponsor: Novartis

Protocol Title: “ELIVATE-A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy, compared to each monotherapy, for treatment of adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis”

Protocol # CLJN452D12201C (Radiology involvement Liver Biopsy, MRIs)

2017- Current (Active, Not Recruiting)

 

Principal Investigator

NASH

Sponsor: Intercept

Protocol Title: “A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis”

Protocol # 747-303 (Radiology involvement Liver Biopsy, USs)